Company intelligence / Profile preview

Ikaria, Inc.

Hampton, New Jersey, United States

Ownership: Private
Employees: ~750
Development stage: Phase 1

Overview

Ikaria's lead product INOtherapy was FDA-approved for the treatment of hypoxic respiratory failure in term and near-term infants. The company was conducting clinical trials for additional indications and developing advanced drug-delivery systems.

Therapeutic areas: PulmonologyCardiovascularInfectious DiseasesNephrology
Modalities: BiotherapeuticsDrug-delivery systems
Industry: Biotech

Drug pipeline

2 assets

RN0191

Phase 1

Indications: Hypercholesterolemia

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Ikaria, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ikaria, Inc..

Explore the full profile